Cell and Gene Therapy Catapult Invests in Lir Therapeutics to Accelerate Development of Its AI-Driven AAV Design Platform

Key Takeaways

• CGT Catapult backs Lir via Innovate UK’s Cross‑Catapult Pilot.
• Funding targets biological validation and dataset generation for nAAVigator.
• AI‑driven “lab‑in‑the‑loop” platform aims to reduce AAV immunogenicity.
• Successful capsid design could accelerate gene‑therapy pipelines for pharma partners.

Pulse Analysis

Adeno‑associated viruses (AAV) have become the workhorse for delivering genetic payloads in dozens of approved therapies, yet their manufacturing complexity, immune response risk, and limited tissue targeting remain major obstacles. As the global gene‑therapy market is projected to exceed $20 billion by 2030, developers are scrambling for vectors that can be produced at scale while maintaining safety and efficacy. Overcoming these constraints is essential for expanding treatment indications beyond rare diseases into more common conditions such as heart and kidney disorders.

Artificial intelligence is reshaping biotech R&D, and Lir Therapeutics sits at the intersection of AI and viral engineering. Its nAAVigator platform integrates machine‑learning models with high‑throughput screening to iteratively design and test novel capsids in a “lab‑in‑the‑loop” workflow. By automating the search space of millions of possible protein variants, the system promises to identify vectors with reduced immunogenicity, higher potency, and manufacturability that traditional methods would miss. The investment from CGT Catapult, channeled through Innovate UK’s Cross‑Catapult Pilot, not only supplies capital for critical validation studies but also embeds the company within the UK’s specialist ecosystem that couples academic insight with commercial expertise.

If Lir can demonstrate a robust evidence base, the ripple effects could be substantial. Pharma companies would gain a plug‑and‑play toolkit to accelerate pre‑clinical programs, potentially cutting years off development timelines and slashing costs associated with vector failure. Investors are likely to view validated AI‑designed capsids as a de‑risking asset, spurring further funding into the sector. Moreover, a successful UK‑based platform reinforces the country’s position as a hub for next‑generation gene‑therapy innovation, encouraging talent retention and attracting multinational partnerships that could bring transformative medicines to patients worldwide.